{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:12:54Z","timestamp":1783681974101,"version":"3.55.0"},"reference-count":74,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Science and Technology Innovation Project of China Academy of Chinese Medical Sciences","award":["CI2023C015YL"],"award-info":[{"award-number":["CI2023C015YL"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">Helicobacter pylori<\/jats:italic>\n                      (\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      ) infection and its related diseases constitute a significant global public health issue, and the growing antibiotic resistance of\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      poses a serious challenge.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Consequently, the search for sensitive, safe, economical, and readily available therapeutic drugs has become a core challenge in contemporary research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis of randomized controlled trials and observational studies followed the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (2020).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources and methods:<\/jats:title>\n                    <jats:p>\n                      This study conducted a thorough and systematic literature review of PubMed, Web of Science, EMBASE, China National Knowledge Infrastructure, Chinese Scientific Journal Database, and Wanfang Data up to October 16, 2025, using keywords such as minocycline and\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      . The included studies were assessed for risk of bias, and meta-analyses were conducted using Review Manager 5.3 and Stata\/MP 14.0 to estimate the pooled effect sizes. Risk ratios (RR) were used for statistical analysis, and the corresponding 95% confidence intervals (CI) were calculated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Minocycline exhibits pharmacokinetic characteristics including high absorption, strong lipophilicity, tissue permeability, and a prolonged half-life. Beyond its antibacterial effects, it also possesses non-antimicrobial activities such as anti-inflammatory, immunomodulatory, antioxidant, and anti-apoptotic properties. Eighteen studies from six countries indicate that\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      is sensitive to minocycline. This study included 33 clinical trials that evaluated minocycline-containing eradication regimens for\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      infection. Based on pairwise meta-analysis, both the intention-to-treat (ITT; RR\u2009=\u20091.04, 95% CI: 0.99\u20131.08,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.15) and per-protocol (PP; RR\u2009=\u20091.04, 95% CI: 1.00\u20131.08,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.06) analyses showed no significant difference in\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      eradication rates between the minocycline-containing eradication regimen and the control group; however, the overall incidence of adverse reactions was significantly lower (RR\u2009=\u20090.85, 95% CI: 0.78\u20130.92,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.05), while compliance rate was comparable to that of the control group (RR\u2009=\u20091.01, 95% CI: 1.00\u20131.03,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.15). Based on meta-analysis of proportions, the ITT analysis indicated the\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      eradication rate was 83% (95% CI: 79%\u201387%), while the PP analysis showed an eradication rate of 88% (95% CI: 83%\u201392%), an adverse reaction incidence of 29% (95% CI: 23%\u201336%), and compliance rates of 94% (95% CI: 91%\u201396%). The analysis revealed that minocycline-containing regimens exhibited favorable efficacy, safety, and patient compliance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      Minocycline may be considered a viable antibiotic option for the eradication of\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      . Further multicenter, large-scale, high-quality clinical studies are still required to validate this conclusion.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>The review was not registered in PROSPERO, we will do so in future studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562848261464690","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:56:05Z","timestamp":1783428965000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Minocycline-containing therapy in\n                    <i>Helicobacter pylori<\/i>\n                    infection: a systematic review and meta-analysis"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3716-1264","authenticated-orcid":false,"given":"Zhihua","family":"Tian","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoli","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00070-5"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-336027"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327745"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312288"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00281-9"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.11.059"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2020.01.022"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12139"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v30.i17.2354"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198815060-00001"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12071152"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(85)80041-4"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562848251366156"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1973145852"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.671376"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-017-0153-2"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2025.07.031"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.24.14014"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/15216540600732021"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(92)90381-R"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e32830edb15"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/77528"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v16.i8.3624"},{"issue":"3","key":"e_1_3_4_25_2","first-page":"2989","article-title":"Minocycline alleviates LPS-induced cognitive dysfunction in mice by inhibiting the NLRP3\/caspase-1 pathway","volume":"16","author":"Zhan F","year":"2024","unstructured":"Zhan F, Dong Y, Zhou L, et al. Minocycline alleviates LPS-induced cognitive dysfunction in mice by inhibiting the NLRP3\/caspase-1 pathway. Aging (Albany NY) 2024; 16(3): 2989\u20133006.","journal-title":"Aging (Albany NY)"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e21004"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109690"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00144743"},{"issue":"8","key":"e_1_3_4_29_2","first-page":"1013","article-title":"Evaluation of minocycline and cefuzonam for antimicrobial activity against clinical isolates","volume":"47","author":"Igari J","year":"1994","unstructured":"Igari J, Oguri T, Higuchi T. Evaluation of minocycline and cefuzonam for antimicrobial activity against clinical isolates. Jpn J Antibiot 1994; 47(8): 1013\u20131029.","journal-title":"Jpn J Antibiot"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.2.235"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02490036"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.5.720"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5378.1999.99051.x"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000168850.55526.53"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2006.04183.x"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2009.00714.x"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12271"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12313"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4536-8"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8071062"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12956"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002629"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-023-01991-y"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13138"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms12030429"},{"key":"e_1_3_4_46_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.","journal-title":"BMJ"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.09.021"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"issue":"16","key":"e_1_3_4_50_2","first-page":"2766","article-title":"Clinical observation of bismuth quadruple therapy containing minocycline and metronidazolefor Helicobacter pylori infection","volume":"34","author":"Zhang L","year":"2018","unstructured":"Zhang L, Lan Y, Wang Q, et al. Clinical observation of bismuth quadruple therapy containing minocycline and metronidazolefor Helicobacter pylori infection. J Pract Med 2018; 34(16): 2766\u20132769.","journal-title":"J Pract Med"},{"key":"e_1_3_4_51_2","article-title":"Application of minocycline-containing bismuth quadruple therapies as first-line regimens in the treatment of","volume":"2019","author":"Zhang L","year":"2019","unstructured":"Zhang L, Lan Y, Wang Q, et al. Application of minocycline-containing bismuth quadruple therapies as first-line regimens in the treatment of Helicobacter pylori. Gastroenterol Res Pract 2019; 2019: 9251879.","journal-title":"Helicobacter pylori. Gastroenterol Res Pract"},{"issue":"7","key":"e_1_3_4_52_2","article-title":"Application of minocycline in patients with Helicobacter pylori infection allergic to penicillin","volume":"42","author":"Zhang L","year":"2022","unstructured":"Zhang L, Lan Y, Wang Q, et al. Application of minocycline in patients with Helicobacter pylori infection allergic to penicillin. Food Sci Technol 2022; 42(7): e67121.","journal-title":"Food Sci Technol"},{"key":"e_1_3_4_53_2","article-title":"Susceptibility-guided vs. empirical 10-day quadruple treatment for Helicobacter pylori-infected patients: a prospective clinical trial of first-line therapy","volume":"13","author":"Li P","year":"2022","unstructured":"Li P, Jin J, Chen Y, et al. Susceptibility-guided vs. empirical 10-day quadruple treatment for Helicobacter pylori-infected patients: a prospective clinical trial of first-line therapy. Front Microbiol 2022; 13: 973975.","journal-title":"Front Microbiol"},{"key":"e_1_3_4_54_2","volume-title":"Comparison between the efficacy of minocycline-based vs furazolidone-based bismuth quadruple therapy in initial treatment for Helicobacter pylori infection","author":"Wang N.","year":"2023","unstructured":"Wang N. Comparison between the efficacy of minocycline-based vs furazolidone-based bismuth quadruple therapy in initial treatment for Helicobacter pylori infection. Master\u2019s Thesis. Jining Medical University, Jining, 2023."},{"issue":"1","key":"e_1_3_4_55_2","article-title":"Randomized multicenter trial comparing minocycline and ornidazole with classical quadruple therapy in Helicobacter pylori treatment","volume":"15","author":"Lin Y","year":"2025","unstructured":"Lin Y, Lin X, Suo B, et al. Randomized multicenter trial comparing minocycline and ornidazole with classical quadruple therapy in Helicobacter pylori treatment. Sci Rep 2025; 15(1): 16318.","journal-title":"Sci Rep"},{"key":"e_1_3_4_56_2","doi-asserted-by":"crossref","unstructured":"Pang Q. Efficacy and safety of bismuth quadruple therapy containing minocycline and berberine for initial eradication of Helicobacter pylori. Xi\u2019an China: Xi\u2019an Medical University 2025. https:\/\/doi.org\/10.27909\/d.cnki.gxaxy.2025.000017.","DOI":"10.1097\/CM9.0000000000004058"},{"issue":"7","key":"e_1_3_4_57_2","first-page":"1014","article-title":"The application of bismuth quadruple therapy containing minocycline and levofloxacin in patients with Helicobacter pylori infection","volume":"20","author":"Zhang Y","year":"2025","unstructured":"Zhang Y, Zhang L, Lan Y, et al. The application of bismuth quadruple therapy containing minocycline and levofloxacin in patients with Helicobacter pylori infection. China Med 2025; 20(7): 1014\u20131018.","journal-title":"China Med"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.15403\/jgld.2014.1121.234.qrth"},{"issue":"12","key":"e_1_3_4_59_2","first-page":"1013","article-title":"Minocycline quadruple versus tailored therapy in retreatment of Helicobacter pylori infection","volume":"54","author":"Zhang L","year":"2015","unstructured":"Zhang L, Zhou L, Song Z, et al. Minocycline quadruple versus tailored therapy in retreatment of Helicobacter pylori infection. Chin J Intern Med 2015; 54(12): 1013\u20131017.","journal-title":"Chin J Intern Med"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.31083\/ph.2019.9349"},{"issue":"12","key":"e_1_3_4_61_2","first-page":"812","article-title":"Efficacy and safety of rifabutin and furazolidone included triple regimen and minocycline plus furazolidone included quadruple regimen in eradicating refractory Helicobacter pylori infection","volume":"39","author":"Li M","year":"2019","unstructured":"Li M, Wang Z, Zheng S. Efficacy and safety of rifabutin and furazolidone included triple regimen and minocycline plus furazolidone included quadruple regimen in eradicating refractory Helicobacter pylori infection. Chin J Dig 2019; 39(12): 812\u2013816.","journal-title":"Chin J Dig"},{"issue":"11","key":"e_1_3_4_62_2","first-page":"129","article-title":"Study on compound probiotics combined with quadruple salvage therapy in the treatment of Helicobacter pylori infection","volume":"32","author":"Chen Y","year":"2020","unstructured":"Chen Y, Lu S. Study on compound probiotics combined with quadruple salvage therapy in the treatment of Helicobacter pylori infection. Strait Pharm J 2020; 32(11): 129\u2013131.","journal-title":"Strait Pharm J"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-022-02732-6"},{"issue":"05","key":"e_1_3_4_64_2","first-page":"513","article-title":"The application value of the quadruple therapy regimen containing bismuth, minocycline and clarithromycin in the initial treatment patients with Helicobacter pylori infection allergic to penicillin","volume":"33","author":"Han Q","year":"2024","unstructured":"Han Q, Cheng Y, Liu X, et al. The application value of the quadruple therapy regimen containing bismuth, minocycline and clarithromycin in the initial treatment patients with Helicobacter pylori infection allergic to penicillin. Chin J Gastroenterol Hepatol 2024; 33(05): 513\u2013517.","journal-title":"Chin J Gastroenterol Hepatol"},{"issue":"33","key":"e_1_3_4_65_2","first-page":"2887","article-title":"Efficacy of Saccharomyces boulardii combined with minocycline quadruple therapy for Helicobacter pylori infection","volume":"105","author":"Chen L","year":"2025","unstructured":"Chen L, Ding Y, Liu Y, et al. Efficacy of Saccharomyces boulardii combined with minocycline quadruple therapy for Helicobacter pylori infection. Natl Med J China 2025; 105(33): 2887\u20132890.","journal-title":"Natl Med J China"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12334"},{"issue":"23","key":"e_1_3_4_67_2","first-page":"5713","article-title":"Efficacy of rabeprazole\/minocycline\/amoxicillin\/bismuth regimen as first- and second-line therapy for Helicobacter pylori eradication","volume":"38","author":"Pu N","year":"2018","unstructured":"Pu N, Ka S, Tang Z. Efficacy of rabeprazole\/minocycline\/amoxicillin\/bismuth regimen as first- and second-line therapy for Helicobacter pylori eradication. Chin J Gerontol 2018; 38(23): 5713\u20135715.","journal-title":"Chin J Gerontol"},{"issue":"10","key":"e_1_3_4_68_2","first-page":"1133","article-title":"Study on minocycline-containing quadruple therapy regimen as first-line and second-line therapy for eradication of Helicobacter pylori infection","volume":"24","author":"Xu S","year":"2019","unstructured":"Xu S, Hong W, Xuan S. Study on minocycline-containing quadruple therapy regimen as first-line and second-line therapy for eradication of Helicobacter pylori infection. Mod Dig Interv 2019; 24(10): 1133\u20131136.","journal-title":"Mod Dig Interv"},{"issue":"1","key":"e_1_3_4_69_2","first-page":"79","article-title":"Prospective study on the efficacy of bismuth quadruple therapy containing minocycline in the eradication of","volume":"18","author":"Guo Y","year":"2023","unstructured":"Guo Y, Lu Y, Liu X, et al. Prospective study on the efficacy of bismuth quadruple therapy containing minocycline in the eradication of Helicobacter pylori. J Chengdu Med Coll 2023; 18(1): 79\u201382.","journal-title":"Helicobacter pylori. J Chengdu Med Coll"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562848241299734"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.13070"},{"issue":"7","key":"e_1_3_4_72_2","first-page":"413","article-title":"A single-arm study on minocycline combined with metronidazole, rabeprazole, and bismuth potassium citrate for eradication of Helicobacter pylori infection","volume":"26","author":"Zhang M","year":"2021","unstructured":"Zhang M, Cui Z, Pei Z, et al. A single-arm study on minocycline combined with metronidazole, rabeprazole, and bismuth potassium citrate for eradication of Helicobacter pylori infection. Chin J Gastroenterol 2021; 26(7): 413\u2013417.","journal-title":"Chin J Gastroenterol"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.70233"},{"issue":"18","key":"e_1_3_4_74_2","first-page":"2237","article-title":"Minocycline-based quadruple therapy in the retreatment of Helicobacter pylori infection","volume":"20","author":"Zhang L","year":"2017","unstructured":"Zhang L, Lan Y, Fan Y, et al. Minocycline-based quadruple therapy in the retreatment of Helicobacter pylori infection. Chin Gen Pract 2017; 20(18): 2237\u20132240.","journal-title":"Chin Gen Pract"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13022"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848261464690","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562848261464690","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848261464690","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T10:17:38Z","timestamp":1783678658000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848261464690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":74,"alternative-id":["10.1177\/17562848261464690"],"URL":"https:\/\/doi.org\/10.1177\/17562848261464690","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"17562848261464690"}}